Nexalin Technology, Inc.

Stage 4 · Declining · week 11

As of Oct 22, 2026, Nexalin Technology is in Stage 4, the downtrend phase, now in week 11 (since Aug 12, 2026). It closed at $2.03, 95.6% below its 52-week high and below its 200-day average, which is falling.

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. More about the company

$2.03

+0.00% today

$2.1M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is NXL early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 21w

S4 24w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 21w → S1 6w → S4 4w → S1 2w → S2 10w → S3 5w → S2 1w → S3 3w → S2 3w → S3 3w → S4 4w → S1 1w → S2 13w → S3 12w → S4 24w → S1 9w → S4 24w → S1 4w → S4 2w → S1 3w → S4 10w current

Total tracked: 165 weeks across 21 stage runs.

NXL among Medical Devices128th of 141 by relative strength

All 141 →

Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	TXG10x Genomics, Inc.	Stage 2 · wk 48	99	−7.8%
2	RCELAvita Medical, Inc.	Stage 2 · wk 13	98	+40.8%
3	BFLYButterfly Network, Inc. Class A	Stage 2 · wk 26	98	−26.0%
4	HAEHaemonetics Corporation	Stage 2 · wk 17	96	+8.7%
5	GKOSGlaukos Corporation	Stage 2 · wk 25	96	+15.1%
6	AXGNAxogen, Inc.	Stage 3 · wk 2	95	−15.3%
7	NEOGNeogen Corporation	Stage 2 · wk 14	95	−11.7%
8	BVSBioventus Inc. Class A	Stage 2 · wk 15	95	+10.5%
…128	NXLNexalin Technology, Inc.	Stage 4 · wk 11	5	−57.8%

vs 52W High

-95.6%

$2.03 lo$46.50 hi

95.6% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 11

1w13w26w

Week 11, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-82.3%

200 DMA: $11.49 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.02x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-57.8%

-85.9%

-84.3%

YTD

-88.4%

-95.6%

Scan Membership

Breakout Watch

Latest: 2024-11-01

4 appearances in last 60 days. First seen: 2024-04-03.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 11 · Vol 0.02x

2026-10-21S4

Wk 10 · Vol 0.07x

2026-10-20S4

Wk 10 · Vol 0.19x

2026-10-19S4

Wk 10 · Vol 0.04x

2026-10-16S4

Wk 10 · Vol 0.02x

2026-10-15S4

Wk 10 · Vol 0.03x

2026-10-14S4

Wk 9 · Vol 0.03x

2026-10-13S4

Wk 9 · Vol 0.07x

2026-10-12S4

Wk 9 · Vol 0.06x

2026-10-09S4

Wk 9 · Vol 0.05x

2026-10-08S4

Wk 9 · Vol 0.33x

2026-10-07S4

Wk 8 · Vol 0.07x

Moving averages & range

50 DMA

$5.63

200 DMA

$11.49

52W High

$46.50

52W Low

$2.03

5D Low

$2.03

Resistance levels (recent highs)

20d High

$7.55

60d High

$10.95

120d High

$18.30

250d High

$46.50

Next resistance

+271.9%

to 20d High

ROE

-240.3%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.0

Nexalin Technology: quick answers

What stage is Nexalin Technology in?

As of Oct 22, 2026, Nexalin Technology (NXL) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 12, 2026 and is in week 11. What the four stages mean

Is Nexalin Technology in an uptrend?

No. Nexalin Technology is in a Stage 4 downtrend. It trades 82.3% below its 200-day average, which is falling.

How far is Nexalin Technology from its 52-week high?

Nexalin Technology closed at $2.03 on Oct 22, 2026, 95.6% below its 52-week high of $46.50. Its 52-week low is $2.03.

How has Nexalin Technology performed over the past year?

As of Oct 22, 2026, Nexalin Technology is down 95.6% over the past year and down 88.4% so far in 2026.

Which sector and industry is Nexalin Technology in?

Nexalin Technology is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer's disease, and dementia. Nexalin Technology, Inc. is headquartered in Houston, Texas.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.